Customer satisfaction and feedback gives us the energy to keep delivering with high quality and to continue improving our services according to our customers different needs.
Route Map to drug candidate.
– Gunnar Nordvall, Senior Principal Scientist, AlzeCure Pharma AB
Chemnotia helped us by identifying a much more efficient and cost-effective synthetic route to our lead compound. This route has been successfully evaluated and will be implemented as our future manufacturing route.
Route Map to drug candidate.
– Torbjörn Larsson, Director Pharmaceutical R&D, Medivir AB
Chemnotia performed a detailed and comprehensive analysis of one of our challenging drug molecules, and identified several novel and very attractive potential manufacturing routes. After CD selection, time limitations very often make it necessary to use non-optimal synthetic routes to produce subsequent campaign batches. In this context, Chemnotia is a particularly useful resource.
Route Maps to drug candidates.
– Arne Grumann, Vice President R&D, Fermion Oy / Orion Group
Chemnotia shows a high degree of professionalism. Excellent expertise, thorough literature research, speed, clear reporting and great communication round up the picture. Much recommended!
Route Map to front runner.
– Bengt von Mentzer, CEO Pharmnovo
Chemnotia’s analysis enables us to reduce costs substantially already when ordering material of our lead compound for the next campaign.
New enantioselective synthetic routes to a drug candidate, to avoid resolution.
– Clas Sonesson, CSO IRL
Chemnotia has supported us in an excellent way, and the new suggested enantioselective routes seem to be very attractive from a scientific and commercial point of view.
Route Maps to front runners and support for compound design.
– Joakim Larsson, Lead Chemist Red Glead Discovery AB
With Chemnotia’s input we could reach our chemistry objectives in lead optimization without extending project time lines.
support for compound design.
– Johan Evenäs, CEO Red Glead Discovery AB
Chemnotia’s agile and informed support really decreases the activation energy for us to get things done.
Contract manufacturing organization
New synthetic routes to a "soon to be marketed" drug.
– Process Development Manager
We are very pleased with your report – you have identified several possible routes which we had not thought of ourselves
Karolinska Development company
- -Evaluation of existing route to front runner (safety, scalability), suggestions for improvements.
- -New synthetic routes to the front runner (IP, stereocontrol, environmental impact).
New synthetic routes to a group of challenging targets.
– Fredrik von Kieseritkzy, PhD, CEO Arubedo AB
We contacted Chemnotia for a retrosynthetic analysis of a set of highly challenging targets, and we were impressed by the outcome and had great use of Chemnotia's report.